Pakola was Chief Medical Officer at Aerpio Pharmaceuticals. is the Chief Medical Officer for REGENXBIO. in Biology from Fordham University, and completed a post-doctoral fellowship at the Mount Sinai School of Medicine before entering the practice of law. from Fordham University School of Law, her Ph.D., M.S. Leslie Misrock, affectionately known as the "father of biotechnology patent law.” Most recently, she was a member of the team representing Myriad in Association for Molecular Pathology v. Coruzzi was one of the first members of Pennie & Edmonds’ biotechnology group founded by S. Her practice encompassed all aspects of patent law, including prosecution, litigation and appeals, in a variety of disciplines in the life sciences, including genetic engineering, molecular biology, virology, vaccines, immunology, therapeutic antibodies, other biologic and small molecule therapeutics, diagnostics, drug discovery, and drug delivery. Coruzzi was a partner at Jones Day, preceded by Pennie & Edmonds, LLP where she counseled clients on patent strategies for biotech and pharmaceutical therapeutics and diagnostics. Coruzzi is the Executive Vice President of Intellectual Property at REGENXBIO. at Albany College of Pharmacy in New York and completed his postdoctoral fellowship at Rutgers University in New Jersey. Prior to Genentech, he worked at Eyetech Pharmaceuticals as part of the initial team submitting the New Drug Application for Macugen and at Novartis Pharmaceuticals in the New Product Commercialization group. and earlier in his career, held several positions at Genentech as part of the team that developed and launched Lucentis. Palanki served as Director of Global Marketing and Sales at NeoVista, Inc. where he led the commercial launch for Jetrea, a novel proteolytic enzyme therapy for symptomatic vitreomacular adhesion. Preceding Santen, he was Global Head of Marketing and Sales at Thrombogenics, Inc. Prior to joining REGENXBIO, he was Senior Vice President of Commercial for all of Americas at Santen Inc. Palanki brings more than 15 years of experience in ophthalmology across pharmaceutical strategy and development, marketing, market access, sales, pricing, reimbursement, supply chain, distribution, business development, medical affairs and portfolio planning leadership. Ram Palanki, Pharm.D., joined REGENXBIO Management Team in August of 2018 as the Senior Vice President of Commercial Strategy and Operations. Danos has directed research focused on gene therapy at the Necker - Enfants Malades Hospital in Paris, the French National Centre for Scientific Research and the Pasteur Institute in Paris. Danos was Director of the Gene Therapy Consortium of the University College of London, Scientific Director at Genethon and Senior Director of Research at Somatix Therapy Corporation. Danos served as Senior Vice President, Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals. Danos also co-founded Lysogene, a NAV Technology Licensee focused on the development of gene therapy product candidates for the treatment of Mucopolysaccharidosis Type IIIA. Danos led company efforts dedicated to identifying and developing new technologies for gene transfer and genome engineering. Danos was Senior Vice President, Cell and Gene Therapy at Biogen Inc. Olivier Danos is the Chief Scientific Officer for REGENXBIO.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |